BDBM50406795 Cozaar LOSARTAN POTASSIUM
BDBM50422638 Losartan 5-(Nitrooxy)Pentanoate CHEMBL360220
Losartan CAS_114798-26-4 NSC_3961 BDBM82258
BDBM50422637 Losartan 3-[(Nitrooxy)Methyl]Benzoate CHEMBL186572
- Segarra, V; Crespo, MI; Pujol, F; Beleta, J; Doménech, T; Miralpeix, M; Palacios, JM; Castro, A; Martinez, A Phosphodiesterase inhibitory properties of losartan. Design and synthesis of new lead compounds. Bioorg Med Chem Lett 8: 505-10 (1998)
- Ono, K; Ueda, H; Yoshizawa, Y; Akazawa, D; Tanimura, R; Shimada, I; Takahashi, H Structural basis for platelet antiaggregation by angiotensin II type 1 receptor antagonist losartan (DuP-753) via glycoprotein VI. J Med Chem 53: 2087-93 (2010)
- Kim, TW; Yoo, BW; Lee, JK; Kim, JH; Lee, KT; Chi, YH; Lee, JY Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists. Bioorg Med Chem Lett 22: 1649-54 (2012)
- Radioligand Assay All synthesized ligands were evaluated in a radioligand assay by displacing 125I-[Sar1, Ile8]-Angiotensin II (Perkin Elmer, NEX248050UC) from human AT2R fused to Cb23 or human/rodent/cynomolgus/minipig/dog WT AT2R in HEK-293 cells membrane preparations, using C21 (Vicore Pharma) and Angiotensin II (endogenous ligand) as reference. The affinity was determined using an eight-point dose-response curve, each point performed in duplicates. The compounds were also evaluated in a counterscreen binding assay for displacement of 125I-[Sar1, Ile8]-Angiotensin II binding to human AT1R in HEK-293 cell membranes. For AT1R, the percent displacement was determined at 1 μM and 10 M (in duplicates) or using an eight-point dose-response curve, each point performed in duplicates with Candesartan and Losartan used as reference.For the AT2R/AT1R binding assays, cell membranes, expressing AT2R_Cb23, AT2R or AT1R, were incubated with 0.05 nM 125I-[Sarl, Ile8]-Ang II. The ligand competition assay was performed in a total volume of 100 μL assay buffer (50 mM Tris, 5 mM MgCl2, 1 mM EDTA, 0.1% BSA, pH 7.4), at concentrations ranging from 1 μM to 10 μM. For each experiment, each ligand concentration was tested in duplicate. Non-specific binding (NSB) was determined by the inclusion of 10 μM unlabeled [Sarl]-Ang II (Sigma Aldrich). The reaction was initiated by the addition of radioligand, after which the plates were incubated at 25° C. for one hour. The reaction was terminated by rapid filtration using a vacuum harvester, applying six washes with 100 μL of ice-cold wash buffer (50 mM Tris.HCl, pH 7.4). The filter plates GF/C (Perkin Elmer) were pre-soaked in 0.5% PEI. The residual amount of radioactivity was determined via liquid scintillation counting. IC50 values, representing the concentration at which each ligand displaced 50% of 125I-[Sarl, Ile8]-Ang II, were calculated using GraphPad Prism 7.02 by applying a Non-linear regression equation (variable slope, four parameters) on the data.